CSIMarket Company Name, Ticker, Competitors, else..
 
Avita Medical Inc   (NASDAQ: RCEL)
Other Ticker:  
 
 
Price: $5.1600 $-0.27 -4.972%
Day's High: $5.5 Week Perf: -12.24 %
Day's Low: $ 5.03 30 Day Perf: -0.96 %
Volume (M): 401 52 Wk High: $ 14.16
Volume (M$): $ 2,068 52 Wk Avg: $9.26
Open: $5.50 52 Wk Low: $4.71



 Market Capitalization (Millions $) 135
 Shares Outstanding (Millions) 26
 Employees 52
 Revenues (TTM) (Millions $) 72
 Net Income (TTM) (Millions $) -57
 Cash Flow (TTM) (Millions $) -2
 Capital Exp. (TTM) (Millions $) 8

Avita Medical Inc
Avita Medical Inc is a global regenerative medicine company that specializes in the development and commercialization of advanced therapeutic solutions for skin regeneration. The company is known for its innovative technology called ReCell, which enables medical professionals to rapidly and efficiently create a suspension of individual skin cells for use in the treatment of severe burns, chronic wounds, and other skin defects. Avita Medical focuses on improving patient outcomes and quality of life by providing personalized and regenerative treatments that enhance the natural healing process of the body. The company operates with a commitment to delivering advancements in healing and aesthetics through its cutting-edge products and therapies.


   Company Address: 28159 Avenue Stanford Valencia 91355 CA
   Company Phone Number: 367-9170   Stock Exchange / Ticker: NASDAQ RCEL


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BAX   -2.66%    
IART   -8.85%    
ICUI   -6.4%    
MDXG   -5.88%    
MMM   -2.96%    
SYK   -0.53%    
• View Complete Report
   



Clinical Study

Augmenting Wound Care AVITA Medicals RECELL and COHEALYX Transform Healing and Recovery,

Published Mon, Jun 9 2025 5:24 PM UTC

Presented by CSIMarket.com In a groundbreaking presentation at the BBA 2025, AVITA Medical showcased the largest real-world analysis of its RECELL system, highlighting its potential to revolutionize inpatient burn care. Combining technological innovation with economic impact offers encouraging results for healthcare providers and patients alike. This article delves into t...
Clinical Study

AVITA Medical Unveils Cohealyx A Breakthrough Collagen-Based Dermal Matrix Set to Transform Healing Landscapes and Ex...

Published Fri, Apr 4 2025 8:01 AM UTC

In a pivotal move that underscores its commitment to advancing medical technologies, AVITA Medical has announced the U.S. launch of Cohealyx, a revolutionary collagen-based dermal matrix specifically engineered to enhance tissue integration and foster revascularization. This innovative product signifies not just a stride in the realm of wound healing but also opens up new op...
Product Service News

AVITA Medicals FDA Clearance Paves the Way Amidst Financial Challenges An In-Depth Look

Published Thu, Dec 19 2024 10:05 PM UTC

In a significant turn of events for AVITA Medical (NASDAQ: AVTA), the company has recently announced the FDA?s 510(k) clearance for its innovative product, Cohealyx. This regulatory approval expands AVITA s addressable market, suggesting new growth opportunities that could bolster its standing in the competitive healthcare landscape. However, this achievement arrives on the ...
Partnership

In a significant strategic move aimed at broadening its geographical footprint, AVITA Medical has announced...

Published Tue, Nov 12 2024 9:03 PM UTC

AVITA Medical Expands RECELL Product Platform to Australia and New Zealand through Exclusive Distribution Agreement In a significant strategic move aimed at broadening its geographical footprint, AVITA Medical has announced an exclusive distribution agreement poised to introduce its innovative RECELL product platform to the markets of Australia and New Zealand. This developm...
Announcement

Avita Medicals Third Quarter Navigating Challenges Amidst Market Performance

Published Thu, Nov 7 2024 9:03 PM UTC

Avita Medical Inc. a biotech firm specializing in regenerative medicine, has released its financial results for the third quarter, revealing a mixed bag of outcomes that has left investors concerned about its trajectory. While the company s innovative skin treatment products demonstrate potential in a rapidly evolving healthcare landscape, recent stock performance has not be...






Avita Medical Inc's Segments
RPK    51.31 % of total Revenue
PermeaDerm    32.41 % of total Revenue
Commercial Sales    99.65 % of total Revenue
Commercial Sales RECELL    95.47 % of total Revenue
Commercial Sales Other Wound Care Products    3.17 % of total Revenue
Commercial Sales Lease Revenue    1.02 % of total Revenue
Deferred Commercial Revenue Recognized    0.04 % of total Revenue
BARDA Revenue For Right of First Access    0.3 % of total Revenue
United States    95.91 % of total Revenue
Japan    3.42 % of total Revenue
European Union    0.26 % of total Revenue
Australia    0.22 % of total Revenue
United Kingdom    0.19 % of total Revenue





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com